Cannabidiol for Pediatric Epilepsy
Quick Facts
What Is Cannabidiol Treatment for Pediatric Epilepsy?
Cannabidiol, often shortened to CBD, is one of the main non-intoxicating compounds found in cannabis, but prescription CBD for epilepsy is not the same as over-the-counter cannabis products. The medicine used in epilepsy care is pharmaceutical-grade, standardized, and prescribed under medical supervision because dosing, drug interactions, and liver monitoring matter.
The strongest clinical evidence is for severe developmental epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. In 2018, the U.S. Food and Drug Administration approved Epidiolex, an oral cannabidiol solution, for seizures associated with these rare epilepsy syndromes, later expanding use to seizures associated with tuberous sclerosis complex. Newer pediatric reports are now exploring whether similar benefits may extend to additional drug-resistant epilepsy patterns.
How Could CBD Reduce Seizures in Children With Drug-Resistant Epilepsy?
Unlike tetrahydrocannabinol, or THC, cannabidiol does not produce a cannabis “high.” Its antiseizure effects appear to involve multiple molecular targets rather than one simple receptor switch. Laboratory and clinical research suggests CBD may affect neuronal excitability, calcium signaling, inflammatory pathways, and neurotransmitter systems that can contribute to seizure generation.
For families, the practical point is that CBD is generally studied as an add-on treatment, not as an immediate replacement for existing antiseizure medicines. Clinicians usually consider it when seizures remain frequent despite appropriate standard therapy, especially in epilepsy syndromes where randomized trials or specialist guidelines support its use.
What Should Parents Know Before Asking About CBD for Epilepsy?
Prescription cannabidiol can cause side effects, including sleepiness, diarrhea, reduced appetite, and changes in liver enzyme tests. The risk of liver enzyme elevations is higher when CBD is combined with some other antiseizure medicines, especially valproate, which is why blood test monitoring is part of careful treatment.
Families should avoid substituting commercial CBD oils for regulated prescription treatment. Nonprescription products can vary in concentration and purity, and some may contain THC or contaminants. For children with severe epilepsy, the safest approach is a neurologist-led treatment plan that includes verified formulation, gradual dosing, interaction review, and clear seizure tracking.
Frequently Asked Questions
No. FDA-approved prescription cannabidiol is indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, not for every type of childhood epilepsy.
Usually not. In clinical practice and major trials, cannabidiol is commonly used as add-on therapy. Any medicine changes should be supervised by a pediatric neurologist.
No. Prescription cannabidiol is manufactured to medical standards with known strength and purity, while over-the-counter CBD products can vary widely and may not be appropriate for children with epilepsy.
References
- U.S. Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. June 25, 2018.
- Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017.
- Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome. The Lancet. 2018.
- Medical Xpress. CBD reduces seizures in drug-resistant pediatric epilepsy, study finds. 2026.